BofA analyst Tazeen Ahmad lowered the firm’s price target on Merus (MRUS) to $70 from $73 and keeps a Buy rating on the shares. The firm updated for Q4 results, cash and share count and increased its operating expense estimates in-line with recent trends.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRUS:
- Merus N.V. Reports 2024 Earnings and Clinical Progress
- Merus’s Promising Clinical Developments and Strategic Advancements Reinforce Buy Rating with $67 Target
- Promising Outlook for Merus’ Petosemtamab: Buy Rating Reaffirmed Amidst Encouraging Clinical Progress
- Merus Receives Buy Rating from Andrew Berens Due to Promising Pipeline and Financial Stability
- Merus’s Strategic Advancements and Clinical Progress Justify Buy Rating
Questions or Comments about the article? Write to editor@tipranks.com